Evidence map›Paper›PMID 33994106›Full record

ArticleTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2021

Efficacy of convalescent plasma therapy in severe COVID-19 patients.

Hilal Akay Cizmecioglu, Mevlut Hakan Goktepe, Sinan Demircioglu, Atakan Tekinalp, Ahmet Cizmecioglu, Ali Kursat Tuna, Huseyin Ozer

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hilal Akay CizmeciogluDepartment of Internal Medicine, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. Electronic address: drhilalakay@hotmail.com.
Mevlut Hakan GoktepeDepartment of Internal Medicine, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. Electronic address: mhakangoktepe@gmail.com.
Sinan DemirciogluDepartment of Hematology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. Electronic address: sinandemircioglumd@gmail.com.
Atakan TekinalpDepartment of Hematology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. Electronic address: atakantekinalp@hotmail.com.
Ahmet CizmeciogluDepartment of Internal Medicine, Faculty of Medicine, Selcuk University, Konya, Turkey. Electronic address: mdahmet2002@gmail.com.
Ali Kursat TunaDepartment of Internal Medicine, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. Electronic address: tunaalikursat@gmail.com.
Huseyin OzerDepartment of Cardiology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey. Electronic address: md.huseyinozer@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe use of convalescent plasma (CP) transfusions is very valuable in the current COVID-19 outbreak, given that there are no specific preventive and therapeutic options. MATERIALS AND

methods50 patients with severe COVID-19 disease treated with convalescent plasma transfusion were included in the study. The efficacy of CP and in which situations it was effective were investigated.

conclusion80 % of the patients recovered, and 20 % died in our study. The mean age of the patients who died was found to be higher than the patients who recovered. CRP, ferritin, D-dimer, neutrophil, MPV, and NLR counts were found to be higher, and lymphocyte and platelet counts were lower in the deceased group after CP. It was determined that patients who received CP within the first five days were hospitalized for a shorter period. DISCUSSION: Administration of CP transfusion within the first five days in severe COVID-19 patients has been shown to reduce hospital stay length.

Indexed as

SARS-CoV-2AgedAged, 80 and overAge FactorsBlood Cell CountCOVID-19COVID-19 SerotherapyC-Reactive ProteinFemaleFerritinsFibrin Fibrinogen Degradation ProductsHospital MortalityHospitals, UniversityHumansImmunization, PassiveLength of StayC-Reactive ProteinFerritinsFibrin Fibrinogen Degradation Productsfibrin fragment DConvalescent plasmaCOVID-19Early transfusionSARS-CoV-2

Identifiers

PMID33994106
PMCPMC8106203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.